Prelude Therapeutics appoints Dr. Charles Q. Morris as Chief Medical Officer effective April 20, 2026

Prelude Therapeutics Inc

Dr. Morris, age 61, brings over 30 years of oncology drug development experience; most recently CMO at Lava Therapeutics.
Annual base salary of $535,000, target bonus of 40% of base, and option for 450,000 PRLD shares vesting over 4 years.
Severance provides 9 months salary/benefits (or 12 months plus full bonus and equity acceleration in change-of-control context).
Company highlights his role will be critical as lead programs in MPN and ER+ breast cancer enter clinical development in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.